Cell replacement therapies for neurodegenerative disease have focused on transplantation of the cell types affected by the pathological process. Here we describe an alternative strategy for Parkinson's disease in which dopamine neurons are generated by direct conversion of astrocytes. Using three transcription factors, NEUROD1, ASCL1 and LMX1A, and the microRNA miR218, collectively designated NeAL218, we reprogram human astrocytes in vitro, and mouse astrocytes in vivo, into induced dopamine neurons (iDANs). Reprogramming efficiency in vitro is improved by small molecules that promote chromatin remodeling and activate the TGF, Shh and Wnt signaling pathways. The reprogramming efficiency of human astrocytes reaches up to 16%, resulting in iDANs with appropriate midbrain markers and excitability. In a mouse model of Parkinson's disease, NeAL218 alone reprograms adult striatal astrocytes into iDANs that are excitable and correct some aspects of motor behavior in vivo, including gait impairments. With further optimization, this approach may enable clinical therapies for Parkinson's disease by delivery of genes rather than cells.
A r t i c l e s
Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of midbrain dopamine neurons (mDAs) in the substantia nigra. Current treatments for the disease focus on symptomatic management through restoration of dopaminergic activity 1 but do not alter the progressive neurodegeneration. There is therefore a clear medical need for disease-modifying therapies. Cell replacement therapy has been proposed as one such approach. Initial efforts were based on the use of fetal midbrain tissue as a source of mDAs for transplantation 2, 3 . However, difficulties in obtaining and standardizing fetal tissue led to the search for alternative cell sources, such as stem cells or reprogrammed cells 4, 5 . Following the discovery that somatic cells can be reprogrammed into induced pluripotent stem (iPS) cells 6 , we and others showed that rodent and human terminally differentiated somatic cells of meso-, endo-and ectodermal origin can be directly reprogrammed into different somatic cells, such as induced neurons (iNs) [7] [8] [9] . Moreover, both rodent and human fibroblasts have been reprogrammed into iDANs [10] [11] [12] [13] capable of bringing some functional recovery after transplantation to animal models of Parkinson's disease 11, 12 .
More recently, direct in vivo reprogramming of adult glial cells has emerged as a possible approach for cell replacement therapy that would avoid the use of cell transplantation and immunosuppression. To date, iDANs have been generated only from mouse astrocytes in vitro 14 . In vivo, mouse glial cells have been reprogrammed to different types of neurons 5, [15] [16] [17] [18] [19] [20] [21] [22] [23] , but not iDANs 22 .
Here we undertake the first two steps toward the development of direct in vivo reprogramming as a therapeutic approach for Parkinson's disease. First, we demonstrate reprogramming of human astrocytes into excitable iDANs in vitro. This is achieved using the NeAl218 cocktail and is further improved by treatment with small molecules. Second, we show direct in vivo reprogramming of adult striatal mouse astrocytes into functional iDANs, leading to rescue of spontaneous motor behavior, such as gait alterations, and correction of some aspects of drug-induced motor behavior in a unilateral 6-hydroxydopamine (6-OHDA) mouse model of Parkinson's disease. Our findings widen the spectrum of demonstrated cell fate switches of human somatic cells and suggest that direct in vivo astrocyte reprogramming is a viable potential strategy to restore motor function in Parkinson's disease.
RESULTS

Reprogramming immortalized human astrocytes into iDANs
In a first attempt to reprogram human astrocytes into iDANs, we infected a human immortalized astrocyte cell line of fetal origin (hIAs) with different lentiviruses carrying the reverse tet-transactivator (rtTA 24 ) and genes encoding three transcription factors previously found to reprogram fibroblasts into iDANs 10 : ASCL1, LMX1A and NR4A2 (the latter also known as NURR1, collectively referred to as "ALN"). hIAs were cultured in Eagle's Minimum Essential Medium (EMEM) for 5 d and subsequently treated with doxycycline for 10 d to trigger transgene expression (basic protocol, BP; Fig. 1a) . We first induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model A r t i c l e s confirmed that hIAs do not give rise to neurons in the absence of ALN, indicating that they are neither stem-nor neurogenic radial glia-like cells (Supplementary Fig. 1a ). ALN infection gave rise to a small proportion (1.26 ± 0.4%) of tyrosine hydroxylase-positive (TH + ) cells at day 15 (Fig. 1c,d) . However, these cells lacked both neuronal morphology and excitability. This conversion efficiency was considerably lower than the 6 ± 2% obtained previously after infection of human IMR90 fibroblasts with ALN under similar culturing conditions 10 , reflecting cell type differences in reprogramming.
The conversion rate of hIAs into iDANs was improved by incorporating additional signals driving midbrain development (midbrain protocol, MP; Fig. 1b) . hIAs were infected with ALN and treated for 7 d with the chromatin remodeling co-factor ascorbic acid 25 , and the TGFβ and BMP4 inhibitors SB431542 and LDN193189, to improve neural induction 26 . Additionally, 2 d after the start of doxycycline treatment, the medium was changed to KON3, a version of the N3 medium 27 . Midbrain floorplate identity was induced with sonic hedgehog (SHH) and the GSK3β inhibitor CT99021 (ref. 28 ). This protocol sharply increased the number of TH + cells (17.5 ± 4.5%) and induced neuronal morphology as well as co-expression of the early neuronal marker β-IIItubulin (TUBB3), but not microtubule-associated protein 2 (MAP2), marking mature somatodendric axes (Fig. 1c,d) . Notably, infection of hIA cells with a control virus harboring GFP or omission of the ALN transcription factors did not produce TH + or TH + /TUBB3 + cells (Supplementary Fig. 1b) , indicating that viral transduction had no effect per se and that ALN was necessary for the generation of iDANs.
NeAL218 is more efficient than ALN to reprogram human astrocytes into iDANs
We next examined the individual contributions of the ALN transcription factors in determining reprogramming efficiency. We found that AL was more efficient than ALN and A was more efficient than AN, indicating that NR4A2 limited the reprogramming of hIA cells into iDANs (Fig. 1e) . We then investigated whether the conversion efficiency could be further increased by the incorporation of additional factors such as NEUROD1, which improves neural reprogramming of human cells 29 , and miR218, which regulates mDA development 30 . We found that NeAL218 induced more iDANs than ALN (30.97 ± 5.3% vs. 17.5 ± 4.5%, respectively) followed by AL218 and AL (24.7 ± 6.5% and 24.3 ± 5.3%, respectively; Fig. 1e ). In addition, NeAL218 also increased the number of mature MAP2 + iDANs to up to 84.6 ± 1.9% (Fig. 1f) . Moreover, the inclusion of miR218 and NEUROD1 in the reprogramming cocktail increased the expression of typical mDA genes such as SLC6A3 (DAT), FOXA2, EN1 and SLC18A2 (VMAT2) by 5-to 20-fold (Supplementary Fig. 1c ). NeAL218-MP-treated hIAs stained positively for TH, TUBB3 and MAP2, as well as the dopaminergic markers dopamine transporter (SLC6A3) and DOPA-decarboxylase (DDC; Fig. 1g ). However, these cells exhibited simple neuron-like morphologies and lacked membrane properties of excitable mDAs.
Increased iDAN reprogramming quality by chromatin remodeling agents and TGF It has been reported that chromatin remodeling agents such as valproic acid 31 (VPA), 5-aza-2′-deoxycytidine 32 (Dec) and ascorbic acid 33 can improve the efficiency of somatic cell reprogramming. It has also been reported that the sequential induction of epithelial-mesenchymal transition and mesenchymal-epithelial transition increases the efficiency of iPS cell generation 34 . We examined whether a short TGFβ1 pulse, followed by overnight treatment with chromatin remodeling agents (VPA and Dec), and treatment with dual-Smad inhibitors (SB431542 and LDN193189) as well as midbrain patterning signals (CT99021 and purmorphamine) could improve the reprogramming efficiency of astrocytes into iDANs. The efficacy of this 'remodeling TGFβ midbrain protocol' (RTMP, Fig. 2a ) on reprogramming was compared to the previous MP protocol after 13 d of doxycycline induction (Fig. 1b) . While the number of TH + cells was lower with RTMP than with the MP protocol (16.48 ± 8.6% vs. 30.97 ± 5.3%, respectively), the quality of iDAN showing the median as well as the 25th and 75th percentiles. Scale bars, 50 µm. *P < 0.05, **P < 0.001 and ***P < 0.0001.
A r t i c l e s
reprogramming improved, as shown by the presence of MAP2, SYN1 (Synapsin), DDC, SLC6A3, KCNJ6 (GIRK2) and ALDH1A1 in TH + cells (Fig. 2b) . Notably, the number of TH + cells did not vary between days 4 and 10 in the NeAL218-RTMP protocol ( Supplementary Fig. 2a ), but their maturation improved over time (Supplementary Fig. 2b ). As a result, the transcriptomic profiles of iDANs NeAL218-RTMP were closer to those of endogenous human mDA neurons than to those of hIAs (Fig. 2d) . Moreover, real-time qPCR confirmed the expression of midbrain-specific transcription factors (EN1, NR4A2, FOXA2 and PITX3) in cells treated with the NeAL218-RTMP protocol, but not with the NeAL218-MP protocol, or in untreated hIAs (Fig. 2e) . Furthermore, the expression of genes typical of mDA neurons (SLC6A3, SLC18A2) and predominantly expressed in substantia nigra neurons, as KCNJ6 and ALDH1A1, increased, while the expression of CALB1, a marker of ventral tegmental area neurons, decreased (Fig. 2e) . We also detected mature TH + ;MAP2 + neurons with long processes, similar to iDANs reprogrammed from fibroblasts 10, 13 , and the presence of TH + ;SYN1 + structures, as well as TH + ;DDC + , TH + ;SLC6A3 + , TH + ;KCNJ6 + and TH + ;ALDH1A1 + cells (Fig. 2b) . These results suggest that the combination of transcription factors and small molecules in the NeAL218-RTMP protocol efficiently increased the acquisition of midbrain regional identity in hIA-derived iDANs. In addition, reprogramming of hIAs into iDANs NeAL218-RTMP was stable, as removal of doxycycline by day 7 or 10 ( Supplementary  Fig. 2c ) did not change marker expression, cell morphology or survival at day 13 ( Supplementary Fig. 2d) . Finally, analysis of the electrophysiological properties of hIA-derived iDANs NeAL218-RTMP revealed that only a few cells were able to generate single action potentials, even though they had voltage-gated inward and outward currents ( Supplementary Fig. 2e-i) .
Enhanced iDAN functionality by reprogramming of primary human astrocytes Considering that the capacity of hIA to differentiate into excitable mature neurons may be impaired by their immortalization with SV40 (ref. 38) , we examined whether human primary embryonic astrocytes (hPAs) could be reprogrammed into mature functional iDANs. While no spontaneous differentiation was observed when we treated hPAs with the RTMP protocol alone (Supplementary Fig. 3a-c) , we reprogrammed NeAL218-RTMP primary astrocytes into TH + cells with an efficiency of 12.4 ± 2.7% (Fig. 2f) .
hPA cells exposed to the NeAL218-RTMP protocol expressed not only mature neuronal markers (MAP2, RBFOX3 (also known as NEUN) and SYN1) in TH + cells but also appropriate mDA markers, including KCNJ6, SLC6A3, DDC, ALDH1A1 and PBX1 ( Fig. 2k and Supplementary Fig. 3d) . Moreover, calcium imaging revealed the presence of cells responding to depolarizing stimuli with multiple action potentials (Fig. 2g) . A more detailed analysis of membrane properties by patch-clamp electrophysiology identified cells with rapid autonomous spiking activity (Fig. 2h) , inward and outward voltage-gated currents (Fig. 2i) , capacity to generate multiple and broad (1.9 ± 0.2 ms) action potentials in 33% of all rRecorded cells on day 14 in vitro, as well as the presence of delayed voltage rectification (sag) typical of mDA neurons (Fig. 2j) . These results indicate that primary human astrocytes can be reprogrammed into functionally competent iDANs by NeAL218-RTMP in vitro ( Table 1) . 
Direct in vivo conversion of mouse astrocytes into iDANs Next, we investigated whether astrocytes can give rise to iDANs in a mouse model of Parkinson's disease. We used the NeAL218 factors alone, without RTMP medium, in adult mice unilaterally lesioned with 6-hydroxydopamine (6-OHDA 39 ). This animal model of Parkinson's disease induces mDA neuron loss in the ipsilateral ventral midbrain (Supplementary Fig. 4a ), as well as denervation and reactive gliosis in the striatum ipsilateral to the 6-OHDA lesion (Supplementary Fig. 4b ). Two weeks after the 6-OHDA infusion, Tet-regulated NeAL218 or GFP lentiviruses were injected into the ipsilateral striatum of transgenic mice in which the tetracycline transactivator is under the control of the gfap promoter (GFAP-tTA mice, Fig. 3a,b) . This genetic construct allows the expression of transgenes exclusively in astrocytes, in the absence of doxycycline, as shown by the exclusive presence of GFP in striatal GFAP + ;RBFOX3 − cells at 2-13 weeks after GFP lentiviral delivery ( Fig.  3c and Supplementary Fig. 4c) . Notably, no partially reprogrammed GFP + ;TH + cells were detected at 13 weeks (Supplementary Fig. 4d) , and none of the animals developed tumors or died during the course of the experiments. Two weeks after NeAL218 injection, TH + cells were identified at different stages of reprogramming, including TH + ;GFAP + cells with mixed astrocyte-to-neuron morphology, as well as TH + ;GFAP − and TH + ;SLC6A3 + cells with neuronal morphology (Fig. 3d) . We also found that newly generated iDANs were either DCX + (doublecortin, a marker for early migratory neurons) or the mature neuronal marker RBFOX3 + , showing that they mature at variable rates into neurons (Fig. 3d) . Notably, iDANs were abundant by 15 weeks after 6-OHDA injection (14.63 ± 8.5 TH + cells/section; seven sections/animal, n = 7), a finding that distinguishes iDANs from transient lesion-induced striatal neurons, which start decaying 1 week after lesion 40 . Moreover, iDANs, unlike lesioninduced striatal TH + neurons 41 , did not express GAD1/2, somatostatin (SST), parvalbumin (PVALB) or calretinin (CALB2) (Fig. 3e) , indicating that they do not derive from or acquire a striatal neuron phenotype.
Characterization of the maturation and electrophysiological properties of iDANs generated in vivo
We next examined whether iDANs in vivo express the dopamine transporter, Slc6a3, which is present in mDA neurons but absent in TH + striatal neurons 40 . For this purpose we used the GFAP-tTa;SLC6A3 Cre/+ ; Rosa26R Tomato reporter mice (Fig. 4, Supplementary Fig. 4f ) or the GFAP-tTa;SLC6A3 Cre/+ mice injected with intrastriatal flex-Tomato virus (Supplementary Fig. 5a ). Analysis of 6-OHDA-lesioned SLC6A3 reporter mice injected with GFP into the striatum showed no A r t i c l e s SLC6A3 Tomato+ ;TH + cells (Supplementary Fig. 4e) , while NeAL218 injection revealed the presence of SLC6A3-driven Tomato + cells that were identified as TH + iDANs, exhibiting a mature neuronal morphology (Fig. 4a) . These cells also expressed the mature neuronal marker RBFOX3 and transcription factors typical for mDA neurons such as NR4A2 and PBX1 (Fig. 4b) . At a functional level, in acute striatal slices from 6-OHDA-lesioned mice injected with NeAl218, we found that several SLC6A3 Tomato+ cells were able to . Tukey whiskers plot with the median, 10th, 25th, 70th and 90th percentiles. Mann-Whitney rank sum test for apomorphine P = 0.035 and for amphetamine P = 0.917 (two tailed).
(b) Spontaneous ipsilateral rotations (expressed as rotations/15 min) 5 weeks after NeAL218 or GFP injection (naive n = 13, lesion n = 13, GFP n = 6, NeAL218 n = 7). One-way ANOVA, F (3,35) = 6.03; P = 0.002 followed by Holm-Sidak's comparison; lesion vs. naive P = 0.003; GFP vs. naive P = 0.0493 and NeAL218 vs. naive P = 0.843. (c-g) Gait analysis showing: (c) total number of gait cycles (naive n = 24, lesion n = 22, GFP n = 11, NeAL218 low dose n = 7, NeAL218 high dose n = 4). Tukey whiskers plot. Kruskal-Wallis test P < 0.0001 followed by Dunn's comparison; lesion vs. naive P < 0.0001; GFP vs. naive P = 0.0012; NeAL218 low vs. naive P = 0.3622 and NeAL218 high vs. naive P > 0.999. (d) Right, examples of consecutive step cycle for all limbs during walk (naive n =10, 6-OHDA-lesion n = 8, lesion-GFP n = 4 and lesion-NeAL218 mice n = 4). Gait was examined using ventral plane videography system. The horizontal bars represent the time during which a paw makes contact with the floor (direction of travel left to right). Asterisks mark hesitations in the gait cycle. . Bar graphs, mean ± s.e.m. Data were analyzed with one sample t-test with theoretical mean equal to 0 (two-tailed). Naive P = 0.383; lesion P = 0.0218; GFP P = 0.0231 and NeAL218 P = 0.178; and (g) coordination index (phase value) representing rear limbs synchronicity in naive n =10, 6-OHDA-lesion n = 8, lesion-GFP n = 4 and lesion-NeAL218 mice n = 4. Tukey whiskers plot, no outlier found. Kruskal-Wallis test P < 0.0001 followed by Dunn's comparison; lesion vs. naive P < 0.0001; GFP vs. naive P = 0.0193; NeAL218 vs. naive P > 0.999. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
A r t i c l e s take up fluorescent dopamine (FFN206) and release it upon KClinduced depolarization ( Fig. 4c and Supplementary Fig. 5b ), suggesting the presence of active SLC18A2 and SLC6A3 (refs. 42,43) n iDANs. Fluorescence-mediated cell identification also allowed for patch-clamp recordings in striatal slices ex vivo, 5 weeks after viral injection. Electrophysiological recordings revealed the capacity of iDANs to reliably generate action potentials (Fig. 4d-f) . We analyzed data from 28 NeAL218-induced SLC6A3 Tomato+ cells and found that 9 of them were capable of producing action potentials, including action potential trains in 5 of them, with an average maximum frequency approaching 15 Hz (Fig. 4e,f and Supplementary Fig. 5c-e) . Together, these experiments revealed the presence of excitable iDANs expressing midbrain markers, such as SLC6A3-driven Tomato, NR4A2 and PBX1. Moreover, NeAL218-derived SLC6A3 Tomato+ cells presented hyperpolarization-activated currents (I h ) in voltageclamp recordings upon hyperpolarization steps to −90 and −100 mV, (Fig. 4e, insert) , causing delayed voltage rectification (or sag; Fig. 4f , hyperpolarization trace), which is considered a biophysical signature of mDA neurons. In contrast, GFP + cells in animals injected with a GFP lentivirus alone lacked excitability and the capacity to generate action potentials (Supplementary Fig. 5f ). These results show that iDANs are excitable and exhibit properties of mDA neurons.
iDANs rescue spontaneous motor behavior in a 6-OHDA model of Parkinson's disease We then examined whether iDANs could induce motor recovery in GFAP-tTa mice with ipsilateral 6-OHDA lesions, as assessed by druginduced and spontaneous motor activity. Drug-induced circling behavior has been traditionally used in combination with unilateral lesion models to examine the functionality of mDA neurons 44 . Rotations induced by apomorphine decreased in animals treated with NeAL218, compared to GFP, 13 weeks after viral injection (Fig. 5a ). This result indicated that iDANs promoted DA transmission in the DA-depleted striatum, thereby reducing the development of DA receptor sensitization in striatal target neurons, which is the basis of the apomorphine-induced circling behavior 45 . However, there was no effect on rotations induced by amphetamine (Fig. 5a, Supplementary Fig. 5g ), a behavior generated by inhibiting or reversing DA transport by SLC6A3, which leads to an abnormal concentration of DA in synapses. Nonetheless, spontaneous circling behavior, which emerges as a consequence of the severe unilateral loss of striatal DA, was completely rescued by NeAL218, but not by GFP, 5 weeks after viral injection in mice unilaterally injected with 6-OHDA (Fig. 5b) . These results suggest that iDANs NeAL218 do not release the very high levels of DA that are required in the synapses to reduce circling behavior in response to amphetamine, but are capable of correcting basal and postsynaptic deficits in DA transmission.
We then performed a more detailed analysis of spontaneous motor behavior and examined coordinated limb usage during voluntary locomotion, a function that is impaired and relevant for Parkinson's disease patients 46 . Computer-based analysis of spontaneous gait cycles on a treadmill 47, 48 revealed a pronounced decline in motor performance induced by 6-OHDA, resulting in incomplete gait cycles (Fig. 5c) . While injection of GFP lentivirus did not improve gait in lesioned mice, injection of NeAL218 restored the number of complete gait cycles 5 weeks after viral injection in a dose-dependent manner (Fig. 5c) , indicating that the effects of NeAL218 are specific. 6-OHDA lesioned mice also showed sequence irregularities in limb usage resulting in movement fragmentation (Fig. 5d) and reduced the percentage of gate cycles with correct paw usage (Fig. 5e) . These behaviors were not modified by GFP lentiviral injection but were rescued by NeAL218 to a level similar to that of naive mice. Similarly, axial symmetry and gait, two parameters typically altered in Parkinson's disease patients 46 and Parkinson's disease mouse models 49 , were restored in NeAl218-injected mice, allowing performances similar to that of naive animals (Fig. 5f,g ). These results demonstrate that direct in vivo reprogramming of astrocytes into iDANs counteracted deficits in spontaneous motor function in experimental Parkinsonism that are relevant to the disease.
DISCUSSION
Previous studies have shown that rodent astrocytes can be reprogrammed into induced neurons 5, [15] [16] [17] [18] [19] [20] [21] [22] [23] , but a dopaminergic phenotype has not yet been obtained from either human astrocytes in vitro or mouse striatal astrocytes in vivo. Here we provide evidence of the capacity of human astroglia to be reprogrammed into iDANs capable of expressing sets of midbrain-specific transcription factors and typical dopaminergic markers, adopting mature neuronal morphology and functionality. Unlike other reprogramming protocols 50 , we found that the ability of NeAL218 to convert astrocytes into iDANs is conserved from mouse to human and from in vitro to in vivo. The efficiency of human astrocyte reprogramming, as well as the acquisition of midbrain markers, sharply increased by sequential treatment with growth factors (TGFβ1) and small molecules (VPA, Dec, SB, LDN, AA, CT and purmorphamine) that promote chromatin remodeling and mimic midbrain development. These findings indicate that human astrocytes are not only amenable to reprogramming but also capable of adequately responding to developmental cues.
A previous study found that intrastriatal delivery of ALN via adenoassociated viruses did not reprogram oligodendrocyte precursors or astrocytes into iDANs in NG2-or GFAP-Cre mice that did not receive a dopaminergic lesion 22 . In our study, GFAP-tTA mice received 6-OHDA injections to mimic the loss of mDA neurons and the reactive gliosis found in Parkinson's disease 51 . The latter may be of particular importance as reactive gliosis is known to increase the number of reprogrammable astrocytes 20 . Moreover, our results show that ALN is less efficient than NeAL218 at reprogramming astrocytes into iDANs in vitro and that a very high titer of NeAL218 lentivirus is required for efficient iDAN generation in 6-OHDA lesioned GFAP-tTA mice.
Our finding that adult mouse striatal astrocytes can be reprogrammed in situ into functional iDANs that rescue some aspects of motor behavior in an animal model of Parkinson's disease supports future development of this strategy as a treatment for the disease. The next steps to be taken toward achieving this goal include improving reprogramming efficiency, demonstrating the approach on human adult striatal astrocytes, developing systems to selectively target human striatal astrocytes in vivo, and ensuring safety and efficacy in humans.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 26 NaHCO 3 , 2.5 KCl, 1.2 NaH 2 PO 4 , 10 HEPES-NaOH, 5 Na-ascorbate, 5 Na-pyruvate, 0.5 CaCl 2 , 8 MgSO 4 and 20 glucose). Then brains were rapidly extracted and immersed in the same solution. Subsequently, 250-µm-thick coronal slices were cut on a vibratome (VT1200S, Leica). Slices encompassing the striatum were selected and equilibrated in artificial cerebrospinal fluid (ACSF) containing (in mM): 124 NaCl, 26 NaHCO 3 , 2.5 KCl, 1.2 NaH 2 PO 4 , 2 CaCl 2 and 2 MgSO 4 at 22-24 °C for 1-4 h before recording. Whole-cell recordings in current-clamp or voltage-clamp mode were made by using MultiClamp amplifier, a DigiData1440 interface, and the pClamp10 software (Molecular Devices). During measurements, slices were continuously perfused with ASCF. The internal pipette solution contained (in mM): 114 K-gluconate, 6 KCl, 10 HEPES, 5 EGTA, 4 ATP-Mg, 0.3 GTP (pH was adjusted to 7.3 with KOH). After recordings, brain slices were immersion fixed with 4% PFA at 4 °C overnight. Electrophysiological data were analyzed using Clampfit 10.0 (Molecular Devices) and SigmaPlot (Systat Software Inc.).
For live imaging, after equilibration in ACSF, the slices were incubated 30 min in the dark in ACSF containing 10 µM FFN 206 (Abcam), then washed for 30 min in the dark in ACSF.
Slices were imaged on a Zeiss LSM700 confocal, and FFN206 release was induced by addition on the slice of KCl 56 mM (final concentration). Data availability. Sequencing data of hIAs, hIDANs and hVM: GSE93528.
